Biogen Scraps Two Alzheimer Drug Trials, Wipes $18 Billion From Market Value
Express Pharma|April 1-15, 2019

The two halted trials were in the final stages of testing aducanumab in patients with mild cognitive impairment due to Alzheimer’s and mild Alzheimer’s disease dementia

Biogen Scraps Two Alzheimer Drug Trials, Wipes $18 Billion From Market Value

BIOGEN and partner Eisai Co are ending two late-stage trials of their experimental Alzheimer’s disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen.

Experts had seen aducanumab as one of the last tests of the hypothesis that removing sticky deposits of amyloid from the brain of patients in earlier stages of the lethal disease could stave off its ravages, which include loss of memory and the ability to care for oneself.

The decision was based on a so-called futility analysis of aducanumab data by an independent monitoring committee that determined the trials had little hope of succeeding.

Eisai in July had touted promising but confusing 18month results from another Alzheimer’s drug, BAN2401, being co-developed with Biogen. That drug failed in a 12-month analysis.

Investors had been cautiously optimistic about aducanumab following early promising data. Without potential future revenue from Alzheimer’s, Biogen has poor growth prospects as it faces patent issues over its big-selling multiple sclerosis drug Tecfidera and possible competition to spinal muscular atrophy drug Spinraza, Wall Street analysts said.

Diese Geschichte stammt aus der April 1-15, 2019-Ausgabe von Express Pharma.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der April 1-15, 2019-Ausgabe von Express Pharma.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS EXPRESS PHARMAAlle anzeigen
Powerful Process Control with IND500x Weighing Indicators
Express Pharma

Powerful Process Control with IND500x Weighing Indicators

Ensuring consistent quality in hazardous environments, particularly in Ex-Areas (Zone 1/21, Division 1), is a critical aspect of industrial operations. The IND500x weighing indicators from METTLER TOLEDO provide a robust solution for these challenging settings, offering optimized safety and productivity.

time-read
1 min  |
November 2024
Ensuring clean room integrity with prime clean reset high-speed doors
Express Pharma

Ensuring clean room integrity with prime clean reset high-speed doors

Prime Clean Reset high-speed doors ensure airtight seals, minimising air permeability and contamination in clean rooms. Designed for sensitive environments, they enhance operational efficiency and meet rigorous regulatory standards, making them ideal for pharmaceutical and biotech industries

time-read
3 Minuten  |
November 2024
Complete environmental monitoring solution - testo Saveris Pharma
Express Pharma

Complete environmental monitoring solution - testo Saveris Pharma

There are several critical applications in the industry like research and development that demand for continuous & reliable monitoring of important environmental parameters.

time-read
3 Minuten  |
November 2024
Adaptive Manufacturing:-The new flexibility in medical device assembly
Express Pharma

Adaptive Manufacturing:-The new flexibility in medical device assembly

Unlike traditional, rigid production lines, B&R's adaptive machines seamlessly adjust to the requirements of each device, dynamically adapting to each unique process

time-read
3 Minuten  |
November 2024
Reshaping pharma safety with active packaging innovations
Express Pharma

Reshaping pharma safety with active packaging innovations

CILICANT is revolutionising active packaging with solutions tailored for the most sensitive formulations. Meet the innovators driving stability, safety, and impurity control in pharma packaging at CPhI India

time-read
1 min  |
November 2024
UNLOCKING GROWTH FRONTIERS
Express Pharma

UNLOCKING GROWTH FRONTIERS

Vadodara Pharma Summit 2024 brought together industry leaders and experts to highlight the city's pivotal role in India's pharma landscape and explore collaborative strategies to strengthen India's pharma innovation ecosystem

time-read
9 Minuten  |
November 2024
Optimising cloud provisioning for pharmaceutical compliance and operational excellence
Express Pharma

Optimising cloud provisioning for pharmaceutical compliance and operational excellence

Suresh Perikala, Senior Engineering Lead - DevOps and Cloud Engineering Practice, Altimetrik

time-read
3 Minuten  |
November 2024
Accelerating pharma's sustainability efforts
Express Pharma

Accelerating pharma's sustainability efforts

Avinaw Prasad, Director, Climate Change & Sustainability, Deloitte India explains why integrating sustainability into the core pharma business strategy is essential for long-term success, analyses key focus areas and policy pushes which can incentivise companies to further evolve on the sustainability path

time-read
5 Minuten  |
November 2024
Drug Repurposing: Unlocking access to rare solutions
Express Pharma

Drug Repurposing: Unlocking access to rare solutions

Drug repurposing, a quick, cost-effective path to deliver existing treatments to patients, can serve to expedite and expand healthcare access for patients with rare diseases

time-read
8 Minuten  |
November 2024
Optimising spend, maximising growth
Express Pharma

Optimising spend, maximising growth

Express Pharma, in partnership with IPA and CHEMEXCIL, powered by SAP, recently organised a thought leadership conclave on 'Reimagining spend management and supply chain' where cross functional experts explored strategies to drive value through supply chain transformation

time-read
7 Minuten  |
November 2024